The LPAC / Fund Manager Update Deck: When the Committee Needs More Than a Performance Snapshot

What the Committee Is Really Voting On

Most first-time GPs approach the LPAC update as a quarterly report with extra slides on key-person changes and a few valuation mark-to-market charts. That framing misses the point by exactly one full governance level. The Limited Partner Advisory Committee does not exist to be informed. It exists to consent, to waive, or to block. Every slide in this deck is either an evidence chain supporting a request for approval — a key-person substitution, a valuation policy variance, an extension of the investment period — or it is noise. Noise gets the deck skimmed. Noise gets the committee’s counsel asking the one question the GP did not want to surface. The private doubt the LP carries into that room is narrow and sharp: ‘If I sign off on this modification, and the fund underperforms next year, did I just fail my fiduciary duty to my own institution’s investment committee?’ The deck does not exist to answer ‘how is the fund doing.’ It exists to give each LP a defensible paper trail for the vote they are about to cast.

Why This Deck Is a Completely Different Animal From the Annual Meeting Presentation

The annual general partner presentation and the LPAC deck share a fund name and a performance table. That is roughly where the resemblance ends. The annual meeting is a relationship exercise — warm, curated, future-oriented. The LPAC meeting is a risk-control checkpoint governed by the Limited Partnership Agreement. The LPA specifies exactly which matters require committee approval, the vote threshold, and the notice period. The deck is a legal-compliant document that happens to use PowerPoint. The SEC does not mandate a specific slide format, but state fiduciary common law and institutional LP policies do set an implicit standard: the GP must show that the committee had all material information before the vote was taken. That changes the editorial logic entirely. A valuation slide that says ‘portfolio company X is marked at 8x trailing EBITDA’ is insufficient. The committee needs to see the methodology, the comparables set, the date of the last third-party valuation, and — critically — whether the GP adjusted the multiple up or down during the quarter and why. Omit any of those and the slide is a gap in the record. The regulatory arc here is not about compliance theater. It is about whether the committee’s consent survives a future LP lawsuit or a clawback claim. That standard does not apply to the fundraising deck or the annual review. It applies here and only here.

Building the Deck: Three Approval Triggers, One Story Shape

The LPAC deck’s internal structure follows the Risk-Mitigation / Regulatory Arc: surface the exposure, document the mitigation, request the consent. That sequence governs every section, regardless of whether the trigger is a valuation event, a key-person departure, or a proposed fund term modification. Start with the NAV and valuation section — not because it is the most important, but because it is the context for every subsequent approval request. Use a waterfall of materiality: aggregate fund NAV change, then sector-level VAMI, then the three largest movers by absolute dollar change. For each material mover, state the valuation methodology used last quarter and the methodology used this quarter. If both are the same, one sentence and move on. If they differ, the slide must explain the rationale and show the impact of the change. The committee’s first unspoken question is: ‘Did the GP just change the rulebook to make the number look better?’ Answer that before they ask. Next, the key-person section. The LPA defines who is key. If that person is leaving, the deck needs two things the committee is looking for: evidence of knowledge transfer (not just a bio of the replacement) and a statement of how the fund’s investment decision-making process remains intact. A generic ‘Sarah brings 15 years of experience’ slide is the wrong answer. The right answer is a comparison of the departing partner’s deal origination and oversight responsibilities with the incoming person’s track record in the same sub-strategy. The committee votes on continuity of judgment, not warmth of recommendation. Third, any required-approval items — investment period extensions, co-investment policy waivers, removal of the GP for cause thresholds. These go last because they are the conclusion the deck has been building toward. The committee reads the evidence chain, then sees the resolution slide. Do not bury the approval language in an appendix. Make it the last content slide before the Q&A deck.

The Craft Gap the LPAC Deck Exposes

Most GPs can build a respectable fundraising deck. The LPAC update is a different craft entirely, and the skills that make a good fundraising deck can actually work against the GP here. Fundraising decks compress complexity into conviction. LPAC decks decompress complexity into transparent reasoning. The same instinct that leads a GP to round a valuation multiple to a tidy number for a prospective LP will produce an omission when a current LP reviews the same data under a governance lens. This is not a data problem. It is an editorial framing problem — the deck is being built for the wrong audience’s decision process. Presentation Gurus works with fund managers on this specific transition: from fundraising narrative to fiduciary disclosure. That means structuring the slide sequence so the committee’s legal counsel can reconstruct the GP’s reasoning from the written record alone, arranging the valuation appendix so the methodology change is visible at a glance rather than buried in a footnote, and writing the key-person section to meet the LPA’s specific consent standard rather than general biographical courtesy. The engagement is a work order, not a template swap — every fund’s LPA creates a different set of approval triggers.

Why the Risk-Mitigation Arc Drives This Room

The committee leans in the moment the GP shows that the fund’s largest position was marked down in Q3 because a comparable public company’s multiple compressed, the GP adjusted the private-company multiple accordingly, and the adjustment was reviewed by the valuation committee before the quarter closed. That evidence chain forms a complete narrative arc — exposure identified, methodology applied, governance step completed. The Risk-Mitigation / Regulatory Arc works because it matches the audience’s attention behavior: the committee skims the macro commentary, slows down on the data tables, and stops cold on any slide that contains an approval trigger. The shape accommodates that scanning pattern by front-loading the context that makes the approval request legible. The GP who tries to warm the room with a thematic market overview before reaching the valuation section will lose the committee’s eyes by slide four. They are not there to be oriented. They are there to be satisfied that their fiduciary duty has been met. The deck that does that clearly, without theatrical storytelling, gives the committee exactly what it needs: a record that justifies the vote they are about to cast.